Robert H. Getzenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert H. Getzenberg has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Eddy S. Leman
The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
6 shared publicationsGrant W. Cannon
The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
4 shared publicationsPrakash Kulkarni
4 shared publicationsYu Zeng
Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland
4 shared publicationsDavid B. Yeater
Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland
3 shared publicationsSteven M. Mooney
Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland
3 shared publications
Latest Publications
- 21 June 2012
- Published by Wiley in The Prostate
- Vol. 73 (2) , 176-181
Circulating fibroblast‐like cells in men with metastatic prostate cancer
BACKGROUND: Metastatic prostate cancer is an incurable disease. During the development of this disease, prostate cancer cells enter the bloodstream as single cells or clusters of cells. Prostate fibroblasts, a cancer‐promoting cell type in the prostate cancer microenvironment, could in theory incorporate into these migrating cell clusters or follow cancer cells into the bloodstream through holes in the tumor vasculature. Based on this idea, we hypothesized that fibroblast‐like cells, defined here as cytokeratin 8/18/19−/DAPI+/CD45−/vimentin+ cells, are present in the blood of men with metastatic prostate cancer.METHODS: Veridex's CellSearch® system was used to immunomagnetically capture EpCAM+ cells and clusters of cells heterogeneous for EpCAM expression from the blood of men with metastatic prostate cancer, localized cancer, and no known cancer, and immunostain them for the presence of cytokeratins 8/18/19, a nucleus, CD45, and vimentin. Fibroblast‐like cells were then quantified.RESULTS: Fibroblast‐like cells were present in 58.3% of men with metastatic prostate cancer but not in any men with localized prostate cancer or no known cancer. The presence of these cells correlated with certain known indicators of poor prognosis: ≥5 circulating tumor cells, defined here as cytokeratin 8/18/19+/DAPI+/CD45− cells, per 7.5 ml of blood, and a relatively high serum prostate‐specific antigen level of ≥20 ng/ml.CONCLUSIONS: The presence of fibroblast‐like cells in the blood may provide prognostic information as well as information about the biology of metastatic prostate cancer. Prostate 73: 176–181, 2013.
- 21 June 2012
- Published by Wiley in The Prostate
- Vol. 73 (2) , 176-181
Circulating fibroblast‐like cells in men with metastatic prostate cancer
BACKGROUND: Metastatic prostate cancer is an incurable disease. During the development of this disease, prostate cancer cells enter the bloodstream as single cells or clusters of cells. Prostate fibroblasts, a cancer‐promoting cell type in the prostate cancer microenvironment, could in theory incorporate into these migrating cell clusters or follow cancer cells into the bloodstream through holes in the tumor vasculature. Based on this idea, we hypothesized that fibroblast‐like cells, defined here as cytokeratin 8/18/19−/DAPI+/CD45−/vimentin+ cells, are present in the blood of men with metastatic prostate cancer.METHODS: Veridex's CellSearch® system was used to immunomagnetically capture EpCAM+ cells and clusters of cells heterogeneous for EpCAM expression from the blood of men with metastatic prostate cancer, localized cancer, and no known cancer, and immunostain them for the presence of cytokeratins 8/18/19, a nucleus, CD45, and vimentin. Fibroblast‐like cells were then quantified.RESULTS: Fibroblast‐like cells were present in 58.3% of men with metastatic prostate cancer but not in any men with localized prostate cancer or no known cancer. The presence of these cells correlated with certain known indicators of poor prognosis: ≥5 circulating tumor cells, defined here as cytokeratin 8/18/19+/DAPI+/CD45− cells, per 7.5 ml of blood, and a relatively high serum prostate‐specific antigen level of ≥20 ng/ml.CONCLUSIONS: The presence of fibroblast‐like cells in the blood may provide prognostic information as well as information about the biology of metastatic prostate cancer. Prostate 73: 176–181, 2013.
- Open Access
- 23 April 2012
- Published by Medknow in Asian Journal of Andrology
- Vol. 14 (3) , 347-348
Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.
- 23 April 2012
- Published by Medknow in Asian Journal of Andrology
- Vol. 14 (3) , 347-348
Open AccessHelping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.
- Open Access
- 20 February 2012
- Published by Medknow in Asian Journal of Andrology
- Vol. 14 (3) , 405-408
Cyr61 is a potential prognostic marker for prostate cancer
Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling that is frequently altered in expression in several types of cancers. In prostate cancer (PCa), Cyr61 is highly expressed in organ-confined disease. Further, Cyr61 expression levels are associated with a lower risk of disease recurrence, and can be quantitatively measured in the serum. Considered together, these results indicate that Cyr61 is a potential and clinically useful tissue, as well as serum-based biomarker for differentiating lethal and non-lethal PCa.
- 20 February 2012
- Published by Medknow in Asian Journal of Andrology
- Vol. 14 (3) , 405-408
Open AccessCyr61 is a potential prognostic marker for prostate cancer
Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling that is frequently altered in expression in several types of cancers. In prostate cancer (PCa), Cyr61 is highly expressed in organ-confined disease. Further, Cyr61 expression levels are associated with a lower risk of disease recurrence, and can be quantitatively measured in the serum. Considered together, these results indicate that Cyr61 is a potential and clinically useful tissue, as well as serum-based biomarker for differentiating lethal and non-lethal PCa.
- 24 October 2011
- Published by Wiley in The Prostate
- Vol. 72 (9) , 966-976
Cyr61 is regulated by cAMP‐dependent protein kinase with serum levels correlating with prostate cancer aggressiveness
BACKGROUND Cysteine‐rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling. Previously, we demonstrated that Cyr61 was highly expressed in prostate cancer (PCa) but that the expression levels were associated with a lower risk of PCa recurrence. In the present study, we demonstrate that serum Cyr61 is a potential biomarker that correlates with PCa aggressiveness. Furthermore, we also explore the potential mechanism underlying the changes in Cyr61 expression during PCa progression. METHODS Cyr61 concentrations in the medium from PCa cell lines and in serum samples obtained from PCa patients were measured by sandwich ELISA. Serum Cyr61 levels were correlated with disease characteristics and the association between Cyr61 expression changes by several types of stimulation or stress and cAMP/cAMP‐dependent protein kinase (PKA) pathway were examined. RESULTS There was a positive correlation between Cyr61 levels in cell supernatants and mRNA expression in these cell lines. Serum Cyr61 levels were significantly higher in non‐organ‐confined PCa patients (116.3 ± 140.2 ng/ml) than in organ‐confined PCa patients (79.7 ± 56.1 ng/ml) (P = 0.031). Cyr61 expression was up‐regulated in response to both lysophosphatidic acid and androgen treatments which promoted PCa cell invasion. Serum starvation and phosphoinositide‐3‐kinase inhibition also resulted in Cyr61 up‐regulation; however, they suppressed cell proliferation. Cyr61 up‐regulation was correlated with an increase in cAMP and suppressed by PKA inhibition. CONCLUSIONS These findings suggest that Cyr61 expression in PCa is regulated by the cAMP/PKA pathway and that circulating Cyr61 levels are a potential serum‐based biomarker for characterizing PCa. Prostate 72:966–976, 2012.
- 24 October 2011
- Published by Wiley in The Prostate
- Vol. 72 (9) , 966-976
Cyr61 is regulated by cAMP‐dependent protein kinase with serum levels correlating with prostate cancer aggressiveness
BACKGROUND Cysteine‐rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling. Previously, we demonstrated that Cyr61 was highly expressed in prostate cancer (PCa) but that the expression levels were associated with a lower risk of PCa recurrence. In the present study, we demonstrate that serum Cyr61 is a potential biomarker that correlates with PCa aggressiveness. Furthermore, we also explore the potential mechanism underlying the changes in Cyr61 expression during PCa progression. METHODS Cyr61 concentrations in the medium from PCa cell lines and in serum samples obtained from PCa patients were measured by sandwich ELISA. Serum Cyr61 levels were correlated with disease characteristics and the association between Cyr61 expression changes by several types of stimulation or stress and cAMP/cAMP‐dependent protein kinase (PKA) pathway were examined. RESULTS There was a positive correlation between Cyr61 levels in cell supernatants and mRNA expression in these cell lines. Serum Cyr61 levels were significantly higher in non‐organ‐confined PCa patients (116.3 ± 140.2 ng/ml) than in organ‐confined PCa patients (79.7 ± 56.1 ng/ml) (P = 0.031). Cyr61 expression was up‐regulated in response to both lysophosphatidic acid and androgen treatments which promoted PCa cell invasion. Serum starvation and phosphoinositide‐3‐kinase inhibition also resulted in Cyr61 up‐regulation; however, they suppressed cell proliferation. Cyr61 up‐regulation was correlated with an increase in cAMP and suppressed by PKA inhibition. CONCLUSIONS These findings suggest that Cyr61 expression in PCa is regulated by the cAMP/PKA pathway and that circulating Cyr61 levels are a potential serum‐based biomarker for characterizing PCa. Prostate 72:966–976, 2012.
- 15 September 2011
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 8 (6) , 2089-2093
Changing the Energy Habitat of the Cancer Cell in Order To Impact Therapeutic Resistance
Somatic cellular evolution is becoming a popular biological explanation for the common rapid development of resistance to almost every form of cancer therapy and against almost every form of advanced human solid tumors. As a result of the historical power of evolution within nature, this common biological interpretation of the failure of cancer therapy is leading to a growing despair for many investigators and a stronger turn toward prevention through lifestyle changes. The absolute explosion of molecular scientific discoveries since 1983, in the reductionist identification of specific cancer therapeutic targets, has failed to deliver the impact in the clinic that many of us would have hoped would have resulted by this time. Personalized molecular medicine may help us reclassify appropriate therapeutic subgroups, but will it significantly impact the overall specific survival times for all of the cancers combined within the organ type for the entire population? How might we approach this therapeutic dilemma by utilizing new therapeutic insights designed on proven principles of evolution? In other words, can we fight the development of therapeutic resistance in cancer cells by turning established aspects of evolution against the survival of cancer cells within the individual patient? Here we review the concepts of changing the heat habitat and microenvironment of the cancer cell to alter the higher order organization and function of DNA. We have proposed that heat may be a major factor in determining the lasting therapeutic effect on many types of far advanced metastatic tumors.
- 15 September 2011
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 8 (6) , 2089-2093
Changing the Energy Habitat of the Cancer Cell in Order To Impact Therapeutic Resistance
Somatic cellular evolution is becoming a popular biological explanation for the common rapid development of resistance to almost every form of cancer therapy and against almost every form of advanced human solid tumors. As a result of the historical power of evolution within nature, this common biological interpretation of the failure of cancer therapy is leading to a growing despair for many investigators and a stronger turn toward prevention through lifestyle changes. The absolute explosion of molecular scientific discoveries since 1983, in the reductionist identification of specific cancer therapeutic targets, has failed to deliver the impact in the clinic that many of us would have hoped would have resulted by this time. Personalized molecular medicine may help us reclassify appropriate therapeutic subgroups, but will it significantly impact the overall specific survival times for all of the cancers combined within the organ type for the entire population? How might we approach this therapeutic dilemma by utilizing new therapeutic insights designed on proven principles of evolution? In other words, can we fight the development of therapeutic resistance in cancer cells by turning established aspects of evolution against the survival of cancer cells within the individual patient? Here we review the concepts of changing the heat habitat and microenvironment of the cancer cell to alter the higher order organization and function of DNA. We have proposed that heat may be a major factor in determining the lasting therapeutic effect on many types of far advanced metastatic tumors.
- Open Access
- 14 September 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 153
Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy
Background: The Cancer/Testis Antigens (CTAs) are an important group of proteins that are typically restricted to the testis in the normal adult but are aberrantly expressed in several types of cancers. As a result of their restricted expression patterns, the CTAs could serve as unique biomarkers for cancer diagnosis/prognosis. The aim of this study was to identify promising CTAs that are associated with prostate cancer (PCa) recurrence following radical prostatectomy (RP). Methods: The expression of 5 CTAs was measured by quantitative multiplex real-time PCR using prostate tissue samples obtained from 72 patients with apparently clinically localized PCa with a median of two years follow-up (range, 1 to 14 years). Results: The expression of CTAs namely, CEP55, NUF2, PBK and TTK were significantly higher while PAGE4 was significantly lower in patients with recurrent disease. All CTAs with the exception of TTK were significantly correlated with the prostatectomy Gleason score, but none were correlated with age, stage, or preoperative PSA levels. In univariate proportional hazards models, CEP55 (HR = 3.59, 95% CI: 1.50-8.60), p = 0.004; NUF2 (HR = 2.28, 95% CI: 1.11-4.67), p = 0.024; and PAGE4 (HR = 0.44, 95% CI: 0.21-0.93), p = 0.031 were significantly associated with the risk of PCa recurrence. However, the results were no longer significant after adjustment for prostatectomy Gleason score. Conclusions: To our knowledge, this is the first study to identify CTAs as biomarkers that can differentiate patients with recurrent and non-recurrent disease following RP and underscores its potential impact on PCa prognosis and treatment.
- 14 September 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 153
Open AccessCancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy
Background: The Cancer/Testis Antigens (CTAs) are an important group of proteins that are typically restricted to the testis in the normal adult but are aberrantly expressed in several types of cancers. As a result of their restricted expression patterns, the CTAs could serve as unique biomarkers for cancer diagnosis/prognosis. The aim of this study was to identify promising CTAs that are associated with prostate cancer (PCa) recurrence following radical prostatectomy (RP). Methods: The expression of 5 CTAs was measured by quantitative multiplex real-time PCR using prostate tissue samples obtained from 72 patients with apparently clinically localized PCa with a median of two years follow-up (range, 1 to 14 years). Results: The expression of CTAs namely, CEP55, NUF2, PBK and TTK were significantly higher while PAGE4 was significantly lower in patients with recurrent disease. All CTAs with the exception of TTK were significantly correlated with the prostatectomy Gleason score, but none were correlated with age, stage, or preoperative PSA levels. In univariate proportional hazards models, CEP55 (HR = 3.59, 95% CI: 1.50-8.60), p = 0.004; NUF2 (HR = 2.28, 95% CI: 1.11-4.67), p = 0.024; and PAGE4 (HR = 0.44, 95% CI: 0.21-0.93), p = 0.031 were significantly associated with the risk of PCa recurrence. However, the results were no longer significant after adjustment for prostatectomy Gleason score. Conclusions: To our knowledge, this is the first study to identify CTAs as biomarkers that can differentiate patients with recurrent and non-recurrent disease following RP and underscores its potential impact on PCa prognosis and treatment.
- 4 April 2011
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 112 (8) , 2125-2137
Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells
The microenvironment is central to many aspects of cancer pathobiology and has been proposed to play a role in the development of cancer cell resistance to therapy. To examine the response to microenvironmental conditions, two paclitaxel resistant prostate cancer (PCa) cell lines (stable and reversible) and one reversible heat resistant cell line were studied. In comparison to their parental cell lines, both paclitaxel resistant cell lines (stable and reversible) were more sensitive to microenvironmental heat, potentially yielding a synergistic therapeutic opportunity. In the two phenotypic cells repopulated after acute heat or paclitaxel treatments, there was an inverse correlation between paclitaxel and heat resistance: resistance to paclitaxel imparted sensitivity to heat; resistance to heat imparted sensitivity to paclitaxel. These studies indicate that as cancer cells evolve resistance to single microenvironmental stress they may be more sensitive to others, perhaps allowing us to design new approaches for PCa therapy. J. Cell. Biochem. 112: 2125–2137, 2011.
- 4 April 2011
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 112 (8) , 2125-2137
Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells
The microenvironment is central to many aspects of cancer pathobiology and has been proposed to play a role in the development of cancer cell resistance to therapy. To examine the response to microenvironmental conditions, two paclitaxel resistant prostate cancer (PCa) cell lines (stable and reversible) and one reversible heat resistant cell line were studied. In comparison to their parental cell lines, both paclitaxel resistant cell lines (stable and reversible) were more sensitive to microenvironmental heat, potentially yielding a synergistic therapeutic opportunity. In the two phenotypic cells repopulated after acute heat or paclitaxel treatments, there was an inverse correlation between paclitaxel and heat resistance: resistance to paclitaxel imparted sensitivity to heat; resistance to heat imparted sensitivity to paclitaxel. These studies indicate that as cancer cells evolve resistance to single microenvironmental stress they may be more sensitive to others, perhaps allowing us to design new approaches for PCa therapy. J. Cell. Biochem. 112: 2125–2137, 2011.
- Open Access
- 25 February 2011
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 16 (1) , 193-201
Prostate cancer‐derived angiogenin stimulates the invasion of prostate fibroblasts
Prostate fibroblasts promote prostate cancer progression by secreting factors that enhance tumour growth and induce the migration and invasion of prostate cancer cells. Considering the role of fibroblasts in cancer progression, we hypothesized that prostate cancer cells recruit these cells to their vicinity, where they are most directly available to influence cancer cell behaviour. To test this hypothesis, we performed modified Boyden chamber assays assessing the migration and collagen I invasion of normal primary prostate fibroblasts (PrSCs) and prostate cancer‐associated fibroblasts (PCAFs) in response to media conditioned by the metastatic prostate cancer cell lines PC‐3, LNCaP and DU145. During 4‐hr incubations, PrSCs and PCAFs migrated and invaded in response to the conditioned media. To identify candidate proteins in the conditioned media that produced these effects, we performed cytokine antibody arrays and detected angiogenin in all three media. Angiogenin‐blocked PC‐3‐conditioned medium, obtained using an anti‐angiogenin polyclonal antibody or angiogenin siRNA, significantly reduced PC‐3‐induced PrSC and PCAF collagen I invasion. Furthermore, angiogenin alone at 1, 2 and 5 ng/ml significantly stimulated PCAF collagen I invasion. These results suggest that PC‐3‐derived angiogenin stimulates the invasion of normal prostate fibroblasts and PCAFs and is sufficient for invasion of the latter. Because prostate fibroblasts play key roles in prostate cancer progression, targeting their invasion using an anti‐angiogenin‐based therapy may be a strategy for preventing or treating advanced prostate cancer.
- 25 February 2011
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 16 (1) , 193-201
Open AccessProstate cancer‐derived angiogenin stimulates the invasion of prostate fibroblasts
Prostate fibroblasts promote prostate cancer progression by secreting factors that enhance tumour growth and induce the migration and invasion of prostate cancer cells. Considering the role of fibroblasts in cancer progression, we hypothesized that prostate cancer cells recruit these cells to their vicinity, where they are most directly available to influence cancer cell behaviour. To test this hypothesis, we performed modified Boyden chamber assays assessing the migration and collagen I invasion of normal primary prostate fibroblasts (PrSCs) and prostate cancer‐associated fibroblasts (PCAFs) in response to media conditioned by the metastatic prostate cancer cell lines PC‐3, LNCaP and DU145. During 4‐hr incubations, PrSCs and PCAFs migrated and invaded in response to the conditioned media. To identify candidate proteins in the conditioned media that produced these effects, we performed cytokine antibody arrays and detected angiogenin in all three media. Angiogenin‐blocked PC‐3‐conditioned medium, obtained using an anti‐angiogenin polyclonal antibody or angiogenin siRNA, significantly reduced PC‐3‐induced PrSC and PCAF collagen I invasion. Furthermore, angiogenin alone at 1, 2 and 5 ng/ml significantly stimulated PCAF collagen I invasion. These results suggest that PC‐3‐derived angiogenin stimulates the invasion of normal prostate fibroblasts and PCAFs and is sufficient for invasion of the latter. Because prostate fibroblasts play key roles in prostate cancer progression, targeting their invasion using an anti‐angiogenin‐based therapy may be a strategy for preventing or treating advanced prostate cancer.
- 18 January 2011
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 112 (4) , 1066-1075
Creatine kinase brain overexpression protects colorectal cells from various metabolic and non‐metabolic stresses
Creatine kinase brain (CKB) is one of three cytosolic isoforms of creatine kinase that is predominantly expressed in the brain. The enzyme is overexpressed in a wide variety of cancers, with the exception of colon cancer, where it is downregulated. The significance of this downregulation remains poorly understood. Here, we demonstrate that overexpression of CKB‐C283S, a dominant‐negative construct that lacks the kinase function but retains its ability to dimerize, causes remarkable changes in cell shape, adhesion, and invasion. Furthermore, it results in increased expression of stromal cell markers such as PAGE4 and SNAIL, suggesting an epithelial‐to‐mesenchymal transition (EMT) in these cells. In cells transfected with a CKB‐expressing construct, CKB localizes not only to the cytosol but also to the nucleus, indicating a structural or kinase role unrelated to ATP storage. Furthermore, overexpression of CFP‐tagged wild‐type (WT) CKB in Caco‐2 colon cancer cells dramatically increased the number of cells in G2/M but had little effect on cell proliferation. Taken together, these data demonstrate that the downregulation of CKB may play an important role in colon cancer progression by promoting EMT. J. Cell. Biochem. 112: 1066–1075, 2011.
- 18 January 2011
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 112 (4) , 1066-1075
Creatine kinase brain overexpression protects colorectal cells from various metabolic and non‐metabolic stresses
Creatine kinase brain (CKB) is one of three cytosolic isoforms of creatine kinase that is predominantly expressed in the brain. The enzyme is overexpressed in a wide variety of cancers, with the exception of colon cancer, where it is downregulated. The significance of this downregulation remains poorly understood. Here, we demonstrate that overexpression of CKB‐C283S, a dominant‐negative construct that lacks the kinase function but retains its ability to dimerize, causes remarkable changes in cell shape, adhesion, and invasion. Furthermore, it results in increased expression of stromal cell markers such as PAGE4 and SNAIL, suggesting an epithelial‐to‐mesenchymal transition (EMT) in these cells. In cells transfected with a CKB‐expressing construct, CKB localizes not only to the cytosol but also to the nucleus, indicating a structural or kinase role unrelated to ATP storage. Furthermore, overexpression of CFP‐tagged wild‐type (WT) CKB in Caco‐2 colon cancer cells dramatically increased the number of cells in G2/M but had little effect on cell proliferation. Taken together, these data demonstrate that the downregulation of CKB may play an important role in colon cancer progression by promoting EMT. J. Cell. Biochem. 112: 1066–1075, 2011.
- 1 December 2010
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (23) , 5908-5913
Decreased Expression of Cyr61 Is Associated with Prostate Cancer Recurrence after Surgical Treatment
Purpose: Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling. Previous studies have suggested that Cyr61 may be a marker for a more aggressive phenotype. In this study, we evaluated the association between Cyr61 staining intensity and subsequent recurrence after surgical treatment of clinically localized prostate cancer. Experimental Design: A study of 229 men with recurrence and 229 controls matched on age, race, pathologic stage, and Gleason sum nested in a cohort of men who underwent radical prostatectomy for clinically localized prostate cancer, utilizing immunohistochemistry analysis of tissue microarray (TMA) sections, was conducted. Odds ratios (OR) of recurrence and 95% confidence intervals (CIs) were estimated using conditional logistic regression. Results: Recurrence was identified in 12.2% of cases, and in 24.0% of controls that had at least 1 TMA spot containing cancer with a staining intensity of 3 (P = 0.001). Taking into account age, pathologic stage and grade, presurgery prostate-specific antigen concentration, and calendar of surgery as a measure of tissue block storage time, men with a Cyr61 staining intensity of 3 were 56% less likely to recur than men with a lower staining intensity (OR = 0.44, 95% CI = 0.22–0.90). Conclusions: High Cyr61 staining intensity in adenocarcinoma was associated with a lower risk of recurrence after surgical treatment of prostate cancer independent of pathologic tumor characteristics. If validated in other sample sets, Cyr61 may serve as a tissue biomarker for stratifying men for risk of recurrence and thus could inform treatment decision making. Clin Cancer Res; 16(23); 5908–13. ©2010 AACR.
- 1 December 2010
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (23) , 5908-5913
Decreased Expression of Cyr61 Is Associated with Prostate Cancer Recurrence after Surgical Treatment
Purpose: Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling. Previous studies have suggested that Cyr61 may be a marker for a more aggressive phenotype. In this study, we evaluated the association between Cyr61 staining intensity and subsequent recurrence after surgical treatment of clinically localized prostate cancer. Experimental Design: A study of 229 men with recurrence and 229 controls matched on age, race, pathologic stage, and Gleason sum nested in a cohort of men who underwent radical prostatectomy for clinically localized prostate cancer, utilizing immunohistochemistry analysis of tissue microarray (TMA) sections, was conducted. Odds ratios (OR) of recurrence and 95% confidence intervals (CIs) were estimated using conditional logistic regression. Results: Recurrence was identified in 12.2% of cases, and in 24.0% of controls that had at least 1 TMA spot containing cancer with a staining intensity of 3 (P = 0.001). Taking into account age, pathologic stage and grade, presurgery prostate-specific antigen concentration, and calendar of surgery as a measure of tissue block storage time, men with a Cyr61 staining intensity of 3 were 56% less likely to recur than men with a lower staining intensity (OR = 0.44, 95% CI = 0.22–0.90). Conclusions: High Cyr61 staining intensity in adenocarcinoma was associated with a lower risk of recurrence after surgical treatment of prostate cancer independent of pathologic tumor characteristics. If validated in other sample sets, Cyr61 may serve as a tissue biomarker for stratifying men for risk of recurrence and thus could inform treatment decision making. Clin Cancer Res; 16(23); 5908–13. ©2010 AACR.